默沙东-话题@MedSci

#默沙东#

121篇内容 | 4322人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259937, encodeId=ced6125993eb1, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, objectType=article, longId=85252, objectId=aeb08525282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeb08525282, replyNumber=0, likeNumber=63, createdTime=2016-12-25, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeb08525282, moduleTitle=喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeb08525282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259936, encodeId=a4fa125993673, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=FDA批准默沙东单抗新药，降低耐药菌复发风险, objectType=article, longId=81657, objectId=9e148165ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e148165ed6, replyNumber=0, likeNumber=125, createdTime=2016-11-03, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e148165ed6, moduleTitle=FDA批准默沙东单抗新药，降低耐药菌复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e148165ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259935, encodeId=8c7512599350a, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=喜讯！默沙东与三星依那西普生物仿制药Brenzys获加拿大卫生部批准, objectType=article, longId=77800, objectId=ebc8e780028, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebc8e780028, replyNumber=0, likeNumber=61, createdTime=2016-09-20, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebc8e780028, moduleTitle=喜讯！默沙东与三星依那西普生物仿制药Brenzys获加拿大卫生部批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebc8e780028)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259934, encodeId=daa7125993415, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格, objectType=article, longId=77041, objectId=3754e70412b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3754e70412b, replyNumber=0, likeNumber=81, createdTime=2016-09-10, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3754e70412b, moduleTitle=喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3754e70412b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259933, encodeId=0c4912599338d, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=Medivation化身“香饽饽” 默沙东或加入竞购大军？, objectType=article, longId=75640, objectId=a5efe564045, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5efe564045, replyNumber=0, likeNumber=53, createdTime=2016-08-24, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5efe564045, moduleTitle=Medivation化身“香饽饽” 默沙东或加入竞购大军？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5efe564045)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259932, encodeId=c7491259932de, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=施贵宝Opdivo PK 默沙东Keytruda，肺癌市场谁胜出？, objectType=article, longId=71963, objectId=4b9fe1963d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b9fe1963d1, replyNumber=0, likeNumber=74, createdTime=2016-07-02, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b9fe1963d1, moduleTitle=施贵宝Opdivo PK 默沙东Keytruda，肺癌市场谁胜出？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b9fe1963d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259931, encodeId=affc12599313f, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=喜讯！默沙东PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌（NSCLC）新适应症获CHMP支持批准, objectType=article, longId=71750, objectId=6a53e17507d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a53e17507d, replyNumber=0, likeNumber=68, createdTime=2016-06-30, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a53e17507d, moduleTitle=喜讯！默沙东PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌（NSCLC）新适应症获CHMP支持批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a53e17507d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259930, encodeId=5384125993090, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期, objectType=article, longId=71400, objectId=0e3be140052, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e3be140052, replyNumber=0, likeNumber=0, createdTime=2016-06-23, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e3be140052, moduleTitle=默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e3be140052)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259929, encodeId=fcc71259929ed, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=ADA 2016：默沙东生物类似物MK-1293治疗1型和2型糖尿病III期临床疗效媲美来得时（Lantus）, objectType=article, longId=71288, objectId=4a51e128881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a51e128881, replyNumber=0, likeNumber=107, createdTime=2016-06-22, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a51e128881, moduleTitle=ADA 2016：默沙东生物类似物MK-1293治疗1型和2型糖尿病III期临床疗效媲美来得时（Lantus）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a51e128881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259928, encodeId=1050125992806, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=BMS与默沙东PD-1单抗一线治疗NSCLC临床数据大PK, objectType=article, longId=70083, objectId=e832e008317, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e832e008317, replyNumber=0, likeNumber=0, createdTime=2016-06-08, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e832e008317, moduleTitle=BMS与默沙东PD-1单抗一线治疗NSCLC临床数据大PK, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e832e008317)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259927, encodeId=5db4125992e16, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东丙肝鸡尾酒Zepatier获欧盟CHMP支持批准，用于基因型1/4丙肝, objectType=article, longId=69399, objectId=49dd69399c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49dd69399c2, replyNumber=0, likeNumber=111, createdTime=2016-05-30, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49dd69399c2, moduleTitle=默沙东丙肝鸡尾酒Zepatier获欧盟CHMP支持批准，用于基因型1/4丙肝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49dd69399c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259926, encodeId=bdcb125992645, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=OCC 2016：携手|当默沙东遇上心血管健康联盟, objectType=article, longId=69895, objectId=7a7f6989578, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a7f6989578, replyNumber=0, likeNumber=89, createdTime=2016-05-29, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a7f6989578, moduleTitle=OCC 2016：携手|当默沙东遇上心血管健康联盟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a7f6989578)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259925, encodeId=052312599252d, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=ASCO 2016 ：默沙东Keytruda临床试验结果喜人, objectType=article, longId=69338, objectId=7750693382c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7750693382c, replyNumber=0, likeNumber=86, createdTime=2016-05-28, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7750693382c, moduleTitle=ASCO 2016 ：默沙东Keytruda临床试验结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7750693382c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259924, encodeId=dbc312599242d, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=FDA受理默沙东Remicade（类克）生物仿制药上市申请, objectType=article, longId=69255, objectId=ba9b69255bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba9b69255bf, replyNumber=0, likeNumber=56, createdTime=2016-05-27, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba9b69255bf, moduleTitle=FDA受理默沙东Remicade（类克）生物仿制药上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba9b69255bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259923, encodeId=c1b21259923f0, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东战胜吉利德，赢取首轮丙肝药专利权大战, objectType=article, longId=68151, objectId=7e776815114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e776815114, replyNumber=0, likeNumber=57, createdTime=2016-05-15, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e776815114, moduleTitle=默沙东战胜吉利德，赢取首轮丙肝药专利权大战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e776815114)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259922, encodeId=335f12599223b, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=FDA授予默沙东PD-1免疫疗法Keytruda第4个突破性药物资格：经典型霍奇金淋巴瘤（cHL）, objectType=article, longId=66949, objectId=653e669497b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=653e669497b, replyNumber=0, likeNumber=75, createdTime=2016-04-23, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=653e669497b, moduleTitle=FDA授予默沙东PD-1免疫疗法Keytruda第4个突破性药物资格：经典型霍奇金淋巴瘤（cHL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=653e669497b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259921, encodeId=f47812599215b, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=第10版《默沙东/默克兽医手册》中文版出版, objectType=article, longId=65779, objectId=a91665e791d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91665e791d, replyNumber=0, likeNumber=46, createdTime=2016-04-02, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91665e791d, moduleTitle=第10版《默沙东/默克兽医手册》中文版出版, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91665e791d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259920, encodeId=0231125992092, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=FDA受理默沙东抗毒素产品bezlotoxumab上市申请，预防艰难梭菌（C.difficile）感染的复发, objectType=article, longId=62805, objectId=ba81628052f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba81628052f, replyNumber=0, likeNumber=0, createdTime=2016-02-03, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba81628052f, moduleTitle=FDA受理默沙东抗毒素产品bezlotoxumab上市申请，预防艰难梭菌（C.difficile）感染的复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba81628052f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259919, encodeId=19b4125991995, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东、Plexxikon强势携手打造肿瘤免疫组合疗法, objectType=article, longId=50549, objectId=9bdb5054940, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bdb5054940, replyNumber=0, likeNumber=77, createdTime=2015-05-13, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bdb5054940, moduleTitle=默沙东、Plexxikon强势携手打造肿瘤免疫组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bdb5054940)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259918, encodeId=06ad125991828, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东免疫疗法Keytruda黑色素瘤一线治疗击败百时美Yervoy, objectType=article, longId=48622, objectId=13964862214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13964862214, replyNumber=0, likeNumber=71, createdTime=2015-03-28, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13964862214, moduleTitle=默沙东免疫疗法Keytruda黑色素瘤一线治疗击败百时美Yervoy, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13964862214)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

默沙东

2020-05-29

yese (审核中...)

前往app查看评论内容

#默沙东#

喜讯！默沙东PD-1免疫疗法Keytruda获日本批准一线治疗PD-L1阳性非小细胞肺癌（NSCLC）

2016-12-25

yese (审核中...)

前往app查看评论内容

#默沙东#

FDA批准默沙东单抗新药，降低耐药菌复发风险

2016-11-03

yese (审核中...)

前往app查看评论内容

#默沙东#

喜讯！默沙东与三星依那西普生物仿制药Brenzys获加拿大卫生部批准

2016-09-20

yese (审核中...)

前往app查看评论内容

#默沙东#

喜讯！FDA授予默沙东免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）优先审查资格和突破性药物资格

2016-09-10

yese (审核中...)

前往app查看评论内容

#默沙东#

Medivation化身“香饽饽” 默沙东或加入竞购大军？

2016-08-24

yese (审核中...)

前往app查看评论内容

#默沙东#

施贵宝Opdivo PK 默沙东Keytruda，肺癌市场谁胜出？

2016-07-02

yese (审核中...)

前往app查看评论内容

#默沙东#

喜讯！默沙东PD-1免疫疗法Keytruda治疗晚期非小细胞肺癌（NSCLC）新适应症获CHMP支持批准

2016-06-30

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期

2016-06-23

yese (审核中...)

前往app查看评论内容

#默沙东#

ADA 2016：默沙东生物类似物MK-1293治疗1型和2型糖尿病III期临床疗效媲美来得时（Lantus）

2016-06-22

yese (审核中...)

前往app查看评论内容

#默沙东#

BMS与默沙东PD-1单抗一线治疗NSCLC临床数据大PK

2016-06-08

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东丙肝鸡尾酒Zepatier获欧盟CHMP支持批准，用于基因型1/4丙肝

2016-05-30

yese (审核中...)

前往app查看评论内容

#默沙东#

OCC 2016：携手|当默沙东遇上心血管健康联盟

2016-05-29

yese (审核中...)

前往app查看评论内容

#默沙东#

ASCO 2016 ：默沙东Keytruda临床试验结果喜人

2016-05-28

yese (审核中...)

前往app查看评论内容

#默沙东#

FDA受理默沙东Remicade（类克）生物仿制药上市申请

2016-05-27

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东战胜吉利德，赢取首轮丙肝药专利权大战

2016-05-15

yese (审核中...)

前往app查看评论内容

#默沙东#

FDA授予默沙东PD-1免疫疗法Keytruda第4个突破性药物资格：经典型霍奇金淋巴瘤（cHL）

2016-04-23

yese (审核中...)

前往app查看评论内容

#默沙东#

第10版《默沙东/默克兽医手册》中文版出版

2016-04-02

yese (审核中...)

前往app查看评论内容

#默沙东#

FDA受理默沙东抗毒素产品bezlotoxumab上市申请，预防艰难梭菌（C.difficile）感染的复发

2016-02-03

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东、Plexxikon强势携手打造肿瘤免疫组合疗法

2015-05-13

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东免疫疗法Keytruda黑色素瘤一线治疗击败百时美Yervoy

2015-03-28

科室
- - 订阅+
  - 更多科室
工具
服务